Fernando Ruiz

Nvidia CEO Jensen Huang just revealed the “five-layer” model of what AI is dependent upon… These 5 layers include: 1. Energy ~ $NBIS, $IREN, $CIFR, $OKLO 2. Chips ~ $NVDA, $AMD, $TSM, $AVGO 3. Cloud Infrastructure ~ $AMZN, $MSFT, $GOOGL, $CRWV 4. Models ~ $META, $ORCL 5. Applications ~ $PLTR, $TSLA All these names will see generational upside in 2026 as AI continues to expand rapidly. Save this for later…

@guo_lin99725 You are over complicating things. 1. There are no secret negotiations. There is nothing to negotiate. This is just Blue Origin trying to launch a reusable rocket for the first time, which led to small delays 2. All the bluebirds are launcher agnostic.

$Asts has a Blue Origin problem. the stock doesn't. I hate delay… it makes me confused… risks was changed bigger… Asts is supposed to launch 45 to 60 satellites in 2026. the first one — BlueBird 7 — was supposed to fly in March. then April 10th. then April 14th. now it's April 16th, and as of 48 hours ago the rocket was still sitting in the assembly building, not even at the launch pad. and the thing is, this is not a surprise. the 28-day gap that should worry you here's what happened. on March 2nd, during the Q4 2025 earnings call, CEO Abel Avellan said BlueBird 7 was expected to launch in March. on March 30th — 28 days later — AST officially circled April 10th as the new target. that's a 28-day information gap. either AST didn't know it was slipping on March 2nd, or it did know and didn't say so. neither version is acceptable for a $36 billion public company. you can decide for yourself which scenario is more likely. companies of this size with these launch timelines generally don't get their dates wrong by four weeks. more likely: AST was negotiating with Blue Origin in private during those 28 days, trying to find a slot, and the market found out when AST decided it was ready to say something publicly. that's not a confidence-inspiring supply chain partner. the April 9th incident, parsed carefully Blue Origin's 2CAT second-stage testing facility on Merritt Island experienced what it called a "high-energy anomaly" on April 9th. a test damaged the building's roof. no injuries. the company announced a two-day delay from April 14th to April 16th on April 10th. here's the part that matters: as of April 10th — the same day Blue Origin announced the two-day delay — the New Glenn rocket was still in the assembly building. it had not been moved to the launch pad at Cape Canaveral. a two-day delay announcement should mean the hardware is ready and waiting. the fact that the rocket was still in the Bay suggests the delay announcement was optimistic even by Blue Origin's own standards. the 2CAT facility is where Blue Origin tests the second stage of New Glenn. if the April 9th anomaly involved hardware slated for NG-3 — and we don't know this for certain, but it's a reasonable inference — then Blue Origin needs to inspect, diagnose, and potentially repair or replace that hardware before flight. two days is not enough time for that. this is why the stock is at $94 instead of $120. the market is watching. the dependency risk nobody is talking about AST needs New Glenn. not just prefers — needs. from the earnings call: New Glenn's 7-meter fairing gives twice the payload volume of 5-meter class commercial launch vehicles and can carry up to 8 of AST's largest Block 2 BlueBird satellites per launch. AST has designed its entire Block 2 satellite form factor around New Glenn's geometry. that means AST cannot simply switch to SpaceX or another launcher if Blue Origin slips. redesigning satellites for a different fairing takes years. AST is locked into New Glenn for the foreseeable future. and Blue Origin, despite two successful flights, is still a developing orbital program with two flights total. the third flight — with a reused first-stage booster for the first time — was scheduled for a month ago, then this week, now next week. that's not a mature launch provider. that's exactly the kind of partner that can compress a competitor's deployment timeline by 12 to 18 months if things go wrong. the silver lining BlueBird 7 itself is safe. AST encapsulated the satellite inside the New Glenn payload fairing on February 19th — well before any of these delays. the satellite is at Cape Canaveral, ready to fly. the accident on April 9th was at Blue Origin's Rocket Park manufacturing facility on Merritt Island, not at the launch site. the satellite is not at risk. #asts #spacestocks #satellite #blueorigin #newglenn #investing

Cerro el mercado y Saylor compro virtualmente + 2000 BTC con $STRC Ademas habrá que ver cuanto suma con MSTR. El producto claramente es un éxito. Saylor aumento el stack de BTC mas el BPS de $MSTR Por eso concentre mas capital en MSTR para el siguiente tramo alcista. 📊 Datos y operativa desde Quantfury : quantfury.com/david/

$GOOGL once the pullback completes will be an opportunity of a lifetime. My son will be very grateful when he's 21. I'm going heavy!

BREAKING: Navy SEAL Team 6 commandos extracted the ejected US F-15E pilot from Iran in a "massive operation" involving hundreds of special operations troops and military personnel, per NYT. This marks the first confirmed US ground operation in the Iran War.

$RDW TRUIST UPGRADED REDWIRE TO BUY FROM HOLD WITH A PRICE TARGET OF $15 (FROM $13). The improving mix and progress on programs, as well as further progress on development programs, lends more confidence that equivalent annual cost charges should potentially moderate in the coming periods, the analyst tells investors in a research note. New CFO Chris Edmunds has set low and achievable targets for 2026, and Golden Dome awards are a catalyst for further backlog growth, the firm says. h/t @spacanpanman

@GutierrezCap_ transhumanica.com/asts/model

Súper interesante lo de $ASTS. Me gustaría preguntaros a los que la lleváis. Si genera un 10% anual de retorno durante la próxima década serían 100bn de market cap. ¿Cuánto FCF esperáis que haga para 2036? ¿Y para 2050?

Investors are rotating out of mega-cap tech stocks at a historic pace: The equal-weight S&P 500 ETF, $RSP, attracted +$5.9 billion in inflows in February, the largest monthly inflow since inception. This exceeds the previous record of +$5.0 billion set in 2023. Over the same period, the Magnificent 7 ETF, $MAGS, saw a record -$388 million in outflows. As a result, $RSP is up +5.5% year-to-date, while $MAGS is down -7.1%. This marks a 12.6 percentage point performance gap in just over two months. Investors seem to be diversifying out of Big Tech.

@LiebermanAustin Are you ok? DUOL MAU +36% YoY

Example of a business that is not (yet) being disrupted and might be a good opportunity: $ADBE Example of a business that very clearly is being disrupted that I’m not even considering buying: $DUOL

Bitcoin’s 4-Year Cycle Just Hit the Danger Zone Watch here: youtu.be/wAAzA7h4Pjo

Our fundamental team use the Monte Carlo simulation to derive a 12 month projection In September when $UPS was at $84, we shared our analysis The Median target was $106 The 90% percentile was $147 Price hit $120 recently We combine our fundamental analysis plus technical analysis together to find undervalued positions

$RKLB / $RDW / $ASTS / $VOYG Golden Dome is getting serious funding. Big ticket items: • $7.2B sensors • $5.6B interceptors • $2.0B for AMTI satellites • $2.55B missile defense • $2.2B hypersonics • $1.98B radars This is a full stack missile shield, from detection to interception, with space at the core.

🚨 $NVO BREAKING: NOVO DOWN -12% PRE-MARKET Novo just posted 23% weight loss with CagriSema and still managed to lose the headline... In other words, I knew this would be bad since they were delayed this announcement... Here's what happened 👇 The News Novo Nordisk released headline results from REDEFINE 4, an 84-week, open-label phase 3 trial that compared once-weekly CagriSema (cagrilintide 2.4 mg plus semaglutide 2.4 mg) against $LLY's tirzepatide 15 mg in 809 people with obesity and at least one comorbidity. Average baseline body weight was 114.2 kg. On the “all adherent” estimand, CagriSema delivered 23.0% weight loss at week 84 versus 25.5% for tirzepatide. That's it. That all that mattered to the market. That's a -12% for $NVO in pre-market. To add some more, on the treatment-regimen estimand, it was 20.2% versus 23.6%. Novo said the trial did not meet its primary endpoint of showing non-inferiority on weight loss versus tirzepatide at 84 weeks. Novo also said safety looked consistent with incretin and amylin-based therapies, with mostly gastrointestinal adverse events. My Take This is a real miss, not a disaster. The drug works. Losing 23% of body weight over 84 weeks is elite medicine. The problem is what the trial was designed to prove. Novo wanted to show CagriSema is not meaningfully worse than tirzepatide on weight loss. It failed that bar, which means Novo cannot market this as “at least as good” in the one matchup that investors care about most. And that's bad. The open-label design matters. Weight is objective, but open-label trials can still influence behaviour, expectations, dose management, and discontinuation patterns. The gap between the two estimands also hints at a practical issue. When you move from ideal adherence to a more real-world framing, both drugs lose some shine, and the relative gap remains. That keeps the burden on Novo to show either better tolerability, better persistence, better cardiometabolic outcomes, or a higher-dose regimen that closes the efficacy gap... Let's hope they won't take another year until they realise higher dose = better effect... Strategically, this reinforces what the market has been pricing for a while. Lilly still owns the “best-in-class weight loss” narrative at the high end, and Novo is now forced to win with breadth, access, oral reach, higher dosing of semaglutide, and next steps like higher-dose CagriSema trials. Not rosy by any means. Novo says REDEFINE 11 is expected to report in the first half of 2027 and a higher-dose phase 3 is planned for the second half of 2026, while the FDA decision on CagriSema for weight management is anticipated in late 2026. So the execution will really matter here. Verdict: Bearish Bearish for the near-term narrative. CagriSema is strong, but it just failed the one comparison that was supposed to help Novo reclaim the crown (or at least get on par with Lilly). So, basically, 23% is a great result... Until your rival prints 25.5% and your primary endpoint says “try again”.

BREAKING: Amazon has officially surpassed Walmart as the world's largest company by revenue, reporting $716.9 billion in 2025 sales.

@SpaceInvestor_D These are just your biased targets

Since Grok is supposedly the best AI at predicting the future, I asked for year-end price targets on these stocks. For fun only, not investment advice. Let me know if you got similar results 👇 Space Sector Prospect (2026): Highly bullish. The global space economy is accelerating, fueled by defense/sovereign spending on satellites & missile defense, commercial mega-constellations (comm + Earth obs), rising launch cadence (new vehicles coming online), lunar economy ramp (Artemis/CLPS follow-ons), in-space data centers/manufacturing, D2D connectivity, and AI integration. Private investment hitting records, government budgets expanding, and commercial revenue share >75% create tailwinds for infrastructure, launch, comms, and observation players—though execution, capital raises, and competition remain risks. $RDW — $20 Redwire (space infrastructure, in-space manufacturing, docking, components) benefits from surging DoD/NASA demand and recent large IDIQ wins (e.g., missile defense). Analyst 12-mo avg ~$13.50 (high $22) from current ~$8 implies 70%+ upside; with 2026 defense tailwinds and operational turnaround, $20 by year-end is realistic (strong buy consensus, recent PT raises to $20). $ASTS — $125 AST SpaceMobile (space-based cellular broadband/D2D) has massive TAM via telco partnerships; 2026 constellation deployments and early revenue could drive re-rating. Current ~$82 already reflects hype, analyst 12-mo avg ~$60–80 (highs to $95–137) lags momentum—successful launches/tests support further 50%+ gain to $125 amid sector comms boom. $RKLB — $95 Rocket Lab (small/medium launch via Electron + developing Neutron, plus space systems) is executing at high cadence with growing backlog. Current ~$67; analyst 12-mo avg ~$73–83 (high $120) points to solid upside. Neutron progress + more launches in 2026 launch-heavy environment justifies ~40% gain to $95. $LUNR — $25 Intuitive Machines (lunar landers, CLPS missions, surface tech) rides the lunar economy wave with multiple NASA/commercial flights planned for 2026. Current ~$16; analyst 12-mo avg ~$17–19 (high $26, recent raises to $25) plus repeat mission success supports push to $25. $PL — $30 Planet Labs (daily global Earth observation constellation + analytics) sees steady demand growth from defense, agriculture, and climate apps. Current ~$22.50; analyst 12-mo avg ~$22 (high $30–33) with bullish recent coverage—2026 data/AI tailwinds and constellation scale drive ~33% upside to $30. $VOYG — $48 Voyager Technologies (defense tech, space solutions, Starlab orbital platforms) is a newer public name with strong backlog in national security and future stations. Current ~$26; analyst 12-mo avg ~$44–45 (high $50) reflects big growth runway—sector defense + in-space infrastructure boom supports ~85% gain to $48 by year-end. These are reasoned point estimates (not guarantees) blending analyst consensus, recent momentum, company-specific catalysts (contracts, launches, deployments), and broad sector growth. Space stocks are volatile—dilution, delays, or macro shifts could alter outcomes. Not financial advice; DYOR

@philliplyle410 @TMFAssociates This is What the short thesis is reduced to 😂 unbelievable

A new employment review for $ASTS suggests most senior engineers aren't local in Midland, among other complaints. "The employees here have developed a fantastic sense of humor to make up for the terrible work conditions." It tracks in the context of possible ongoing production delays.

@icooperTrades What do you think about ethereum medium term (this year)? Seems like there could be a rotation from gold and silver at some point

#Ethereum broke above the parallel on the 13th of Jan, but did not confirm the break out. It then put in some bullish consolidation and retraced back to the parallel. At that point probabilites favoured a move up. BUT, it has now broken back inside and is forming a bear flag. Probabilites now favour a further drop with $2624 next support. If that level is lost, then it tests the bottom of the parallel then $2400 is after. If it can get back above the parallel, $3400 and 3600 are the next resistance levels. $ETH #Crypto #Altcoins

@JavierSanz Tío, eres un básico de verdad. Hazte de una vez un puto análisis de la empresa y comparte tu valoración a 3 años. De verdad crees que somos todos tontos? De verdad crees que un contrato del Golden dome no merece una revalorización?

$ASTS huele a short …… pero vamos el mercado está en modo irracional y con FOMO con ella y es intratable. Me recuerda a Tesla en su momento

@SpaceInvestor_D Honestly, We dont care What You personally do. Its more about What You do using the name “Space Investor” while behaving as a trader with that amount of followers and the corresponding influence. I still appreciate your content (a lot) anyways!

Some are still mad that I exited $RKLB after a 20x or $ASTS after a 5x. Bernard Baruch, billionaire financier and advisor to many US presidents put it best: "I made my millions by selling too soon."

@alc2022 This only means that it was way overvalued at the time. Anyways, this should be a good entry point if DUOL fundamentals keep improving. Q1 and Q2 results should start the reversal! 🫡

$DUOL was also trading at half the price in late 2022 (peak post 2021 pessimism), with 10 times less cash flow than today. By any metric, today’s price is a literal gift.